(NYSE: TMO) Thermo Fisher Scientific's forecast annual revenue growth rate of 6.02% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.8%.
Thermo Fisher Scientific's revenue in 2026 is $45,197,000,000.On average, 29 Wall Street analysts forecast TMO's revenue for 2026 to be $17,932,965,415,040, with the lowest TMO revenue forecast at $17,301,208,924,540, and the highest TMO revenue forecast at $18,740,498,858,485. On average, 29 Wall Street analysts forecast TMO's revenue for 2027 to be $18,899,181,224,040, with the lowest TMO revenue forecast at $18,041,107,261,355, and the highest TMO revenue forecast at $19,837,153,801,700.
In 2028, TMO is forecast to generate $20,057,896,951,910 in revenue, with the lowest revenue forecast at $19,121,039,238,645 and the highest revenue forecast at $21,400,565,304,955.